详情页

当前位置：首页 > 详情页

Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Shanghai PulmonaryHospital, Tongji University School of Medicine, Shanghai/CN, [2]HunanCancer Hospital, Changsha/CN, [3]Harbin Medical University CancerHospital, Harbin/CN, [4]The First Affiliated Hospital of Henan University ofScience and Technology, Luoyang/CN, [5]Shanghai Chest Hospital,Shanghai/CN, [6]The First Affiliated Hospital of Gannan Medical University,Ganzhou/CN, [7]Jilin Cancer Hospital, Changchun/CN, [8]Shandong CancerHospital and Institute, Jinan/CN, [9]The Fourth Hospital of Hebei MedicalUniversity, Shijiazhuang/CN, [10]Fuzhou Tuberculosis Prevention andTreatment Hospital, Fuzhou/CN, [11]Affiliated Cancer Hospital andInstitute of Guangzhou Medical University, Guangzhou/CN, [12]TheAffiliated Hospital of Xuzhou Medical University, Xuzhou/CN, [13]The FifthMedical Center of the General Hospital of Chinese People’s LiberationArmy, Beijing/CN, [14]The First affiliated hospital of Guangxi MedicalUniversity, Nanning/CN, [15]Henan Cancer Hosptal, Zhengzhou/CN, [16]Fujian Cancer Hospital, Fuzhou/CN, [17]Akeso Biopharma, Inc.,Zhongshan/CN

出处：

ISSN：

关键词： NSCLC Ivonescimab first-line treatment

语种：

被引次数：

WOS：

中科院分区：

出版当年[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2024]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2024]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 20.8 最新[2024版] 18.4 最新五年平均 20.8 出版当年[2024版] 18.4 出版当年五年平均 21.1 出版前一年[2023版]

第一作者：

第一作者机构： [1]Shanghai PulmonaryHospital, Tongji University School of Medicine, Shanghai/CN,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC [2]Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China [3]A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations [4]Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405) [5]YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations [6]Treatment and outcome patterns of patients with Waldenstrom's macroglobulinemia: a large, multicenter retrospective review in China [7]Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004) [8]A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable NonSmall Cell Lung Cancer [9]Radiotherapy combined with chemoimmunotherapy improves survival compared to chemoimmunotherapy alone as first-line treatment for oligometastatic esophageal squamous cell carcinoma [10]Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR）